Literature DB >> 24621070

Lessons from Antiangiogenic Cancer Therapy-Induced Hypertension.

Michael Bursztyn1.   

Abstract

Entities:  

Year:  2014        PMID： 24621070      PMCID： PMC8031590          DOI： 10.1111/jch.12266

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  27 in total

1.  Home blood-pressure monitoring in patients receiving sunitinib.

Authors:  Michel Azizi; Antoine Chedid; Stéphane Oudard
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

2.  Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer.

Authors:  Leila Khoja; Gireesh Kumaran; Ying Kiat Zee; Nishanth Murukesh; Ric Swindell; Mark P Saunders; Andrew R Clamp; Juan W Valle; Greg Wilson; Gordon C Jayson; Jurjees Hasan
Journal:  J Clin Gastroenterol       Date:  2014 May-Jun       Impact factor: 3.062

Review 3.  Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature.

Authors:  Giuseppe Lombardi; Fable Zustovich; Patrizia Farina; Pasquale Fiduccia; Alessandro Della Puppa; Valentina Polo; Roberta Bertorelle; Marina P Gardiman; Alberto Banzato; Pietro Ciccarino; Luca Denaro; Vittorina Zagonel
Journal:  Anticancer Drugs       Date:  2013-01       Impact factor: 2.248

4.  Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.

Authors:  Robert J Motzer; Dmitry Nosov; Timothy Eisen; Igor Bondarenko; Vladimir Lesovoy; Oleg Lipatov; Piotr Tomczak; Oleksiy Lyulko; Anna Alyasova; Mihai Harza; Mikhail Kogan; Boris Y Alekseev; Cora N Sternberg; Cezary Szczylik; David Cella; Cristina Ivanescu; Andrew Krivoshik; Andrew Strahs; Brooke Esteves; Anna Berkenblit; Thomas E Hutson
Journal:  J Clin Oncol       Date:  2013-09-09       Impact factor: 44.544

Review 5.  Tumor angiogenesis: therapeutic implications.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

6.  Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1.

Authors:  Nilka de Jesus-Gonzalez; Emily Robinson; Radostin Penchev; Margaret von Mehren; Michael C Heinrich; William Tap; Qian Wang; George Demetri; Suzanne George; Benjamin D Humphreys
Journal:  Am J Hypertens       Date:  2012-07-12       Impact factor: 2.689

7.  Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.

Authors:  Michael L Maitland; Kristen E Kasza; Theodore Karrison; Kristin Moshier; Laura Sit; Henry R Black; Samir D Undevia; Walter M Stadler; William J Elliott; Mark J Ratain
Journal:  Clin Cancer Res       Date:  2009-09-22       Impact factor: 12.531

8.  Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.

Authors:  M Scartozzi; E Galizia; S Chiorrini; R Giampieri; R Berardi; C Pierantoni; S Cascinu
Journal:  Ann Oncol       Date:  2008-10-07       Impact factor: 32.976

Review 9.  Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors.

Authors:  Peter Kruzliak; Jan Novák; Miroslav Novák
Journal:  Am J Hypertens       Date:  2013-10-29       Impact factor: 2.689

10.  Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.

Authors:  Brian I Rini; Darrel P Cohen; Dongrui R Lu; Isan Chen; Subramanian Hariharan; Martin E Gore; Robert A Figlin; Michael S Baum; Robert J Motzer
Journal:  J Natl Cancer Inst       Date:  2011-04-28       Impact factor: 13.506
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.